Previous Close | 8.45 |
Open | 8.52 |
Bid | 8.45 |
Ask | 8.75 |
Strike | 55.00 |
Expire Date | 2024-01-19 |
Day's Range | 8.52 - 8.55 |
Contract Range | N/A |
Volume | |
Open Interest | 1.12k |
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.